HitGen Partner BioAge Labs Doses First Participant in Phase 2 Trial of BGE-102, a Novel Oral NLRP3 Inhibitor for Cardiovascular Risk Reduction

Phase 2BGE-102Positive

AI Analysis

Summary

BioAge Labs, a BIOA-listed company, has dosed the first participant in a Phase 2 trial of BGE-102, a novel oral NLRP3 inhibitor being developed for cardiovascular risk reduction in partnership with HitGen.

Clinical Trial Data

Phase

Phase 2

Outcome Details

first participant dosed

Importance:6/10

Sentiment:

0.60

NLRP3 inhibitororalcardiovascularclinical trialPhase 2

Related Companies

$BIOA

Read the original article

Published by PR Newswire Biotech on July 14, 2026 8:30 AM

Read Original